Medtech: In the 21st century, ‘Artificial Intelligence (AI)’ is not a buzzword—it is the brain of modern medicine. As the ...

The FDA told Regeneron in a complete response letter that while it didn't identify any issues with the safety or efficacy of the drug in its approved indications and dosing regimens, the agency didn't ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License ...

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Dr. Michael Kapusta, MD, FRSCS, Ophthalmologist, talks about advanced (proliferative) diabetic retinopathy and pars plana ...

A group of 18 African ophthalmologists have successfully completed a one-year specialized training program in Diabetic ...